Antioxidant micronutrients for lung disease in cystic fibrosis (Q24235655)

1

0 references

author name string

Denise Adams

2

0 references

Neil Brown

3

0 references

Jeffrey A Johnson

Cochrane Database of Systematic Reviews

4

0 references

publication date

8 December 2010

0 references

published in

0 references

cites work

Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Vitamin A and E deficiency and lung disease in infants with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Vitamin status in treated patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

The occurrence and effects of human vitamin E deficiency. A study in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Managing adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Oral supplementation with a high-fat, high-energy product improves nutritional status and alters serum lipids in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Polyunsaturated fatty acids and tocopherol levels in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Enhanced resistance to oxidation of low density lipoproteins and decreased lipid peroxide formation during beta-carotene supplementation in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Effects of vitamin E and carotenoid status on oxidative stress in health and disease. Evidence obtained from human intervention studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Absorption of Different Doses of Fat Soluble and Water Miscible Preparations of Vitamin E in Children with Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Bioavailability of oral vitamin E formulations in adult volunteers and children with chronic cholestasis or cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Letter: Muscular performance and vitamin E in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Lipid peroxidation cannot be used as a universal criterion of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Vitamin D supplementation for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Update on cystic fibrosis epidemiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Advanced cystic fibrosis lung disease in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Lung infections associated with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Association between pulmonary function and sputum biomarkers in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Vitamin A supplementation for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Interpretative strategies for lung function tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Oxidative Stress in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Update on the biological characteristics of the antioxidant micronutrients: vitamin C, vitamin E, and the carotenoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Oxidative stress in cystic fibrosis: dietary and metabolic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Redundancy, disaggregation, and the integrity of medical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

Nutritional assessment of infants with cystic fibrosis diagnosed through screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Selenium and oxidant injury in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Effect of double-blind cross-over selenium supplementation on lipid peroxidation markers in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Impaired resistance to oxidation of low density lipoprotein in cystic fibrosis: improvement during vitamin E supplementation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Dietary supplementation with multiple micronutrients: no beneficial effects in pediatric cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Longitudinal analysis shows serum carotenoid concentrations are low in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Correction of vitamin E deficiency with fat-soluble versus water-miscible preparations of vitamin E in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Selenium and cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Single- and multiple-dose–response relationships of beta-carotene in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Beta-carotene supplementation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Altered antioxidant status and increased lipid peroxidation in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Supplementation with carotenoids corrects increased lipid peroxidation in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

beta-Carotene, malondialdehyde, and cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Plasma vitamin C concentrations in patients with cystic fibrosis: evidence of associations with lung inflammation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Antioxidant deficiency in cystic fibrosis: when is the right time to take action?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Antioxidant nutrients and chronic disease: use of biomarkers of exposure and oxidative stress status in epidemiologic research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Oxidative stress and lung function

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Axonal dystrophy in the gracile nucleus in congenital biliary atresia and cystic fibrosis (mucoviscidosis): beneficial effect of vitamin E therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Vitamin E supplementation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Vitamin E supplementation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Response to oral beta-carotene supplementation in patients with cystic fibrosis: a 16-month follow-up study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Vitamin E deficiency neuropathy in children with fat malabsorption. Studies in cystic fibrosis and chronic cholestasis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Beta carotene: from biochemistry to clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Long-term oral beta-carotene supplementation in patients with cystic fibrosis - effects on antioxidative status and pulmonary function

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Antioxidant status in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

In vivo lipid peroxidation and platelet activation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Blood and Liver Concentrations of Vitamins A and E in Children with Cystic Fibrosis of the Pancreas

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Evidence for increased oxidative damage in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Neutrophil elastase/alpha 1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral beta-carotene supplementation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021

Lipid peroxidation and antioxidant defenses in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007020.PUB2

7 January 2021